



Applicants: Zauderer *et al.*

Application No.: 10/052,942

Filed: January 23, 2002

For: **Methods of Producing or Identifying Intrabodies in Eukaryotic Cells**

Due Date: n/a

Art Unit: 1639

Examiner: Ponnaluri, P.

Docket: 1821.0090004

Atty: EKS/EJH/T-M

COPY

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF Cover Letter;
2. Third Supplemental Information Disclosure Statement;
3. One page of Form PTO-1449 citing two documents (AS23 and AT23);
4. A copy of each of the cited documents; and
5. One (1) return postcard.

FILE COPY

Please Date Stamp And Return To Our Courier

SKGF_DC1:180077.1

Applicants: Zauderer *et al.*

Application No.: 10/052,942

Filed: January 23, 2002

For: **Methods of Producing or Identifying Intrabodies in Eukaryotic Cells**

Due Date: n/a

Art Unit: 1639

Examiner: Ponnaluri, P.

Docket: 1821.0090004

Atty: EKS/EJH/T-M

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF Cover Letter;
2. Third Supplemental Information Disclosure Statement;
3. One page of Form PTO-1449 citing two documents (AS23 and AT23);
4. A copy of each of the cited documents; and
5. One (1) return postcard.



Please Date Stamp And Return To Our Courier

SKGF_DC1:180077.1

BEST AVAILABLE COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ZAUDERER *et al.*

Appl. No. 10/052,942

Filed: January 23, 2002

For: **Methods of Producing or
Identifying Intrabodies in
Eukaryotic Cells**

Confirmation No. 1028

Art Unit: 1639

Examiner: Ponnaluri, P.

Atty. Docket:
1821.0090004/EKS/EJH/T-M

Third Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed on July 1, 2003, in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not

be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Third Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.

Statement under 37 C.F.R. 1.704(d). Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.¹

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Elizabeth J. Haanes, Ph.D.


Attorney for Applicants

Registration No. 42,613

Date: September 22, 2003
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

::ODMAMHODMA\SKGF_DC1;179681;2
SKGF Rev. 12/1802 mac; Rev. 08/07/03 svb

¹Please note that, due to inclement weather associated with Hurricane Isabel, the United States Patent and Trademark Office was closed on September 18 and 19, 2003.

	FORM PTO-1449	ATTY. DOCKET NO. 1821.0090004/EKS/EJH/T-M	APPLICATION NO. 10/052,942
	THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	APPLICANT Zauderer et al.	
	FILING DATE January 23, 2002	GROUP 1639	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS	<u>23</u>	Rondon, I.J., and Marasco, W.A., "Intracellular Antibodies (Intrabodies) For Gene Therapy of Infectious Diseases," Annu. Rev. Microbiol. 51:257-283, Annual Reviews Inc. (1997).
	AT	<u>23</u>	International Search Report for International Application No. PCT/US02/01677, mailed August 19, 2003.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.